PTEN and head and neck squamous cell carcinoma: Copanlisib in combination with cetuximab is being evaluated in phase 1 and phase 2 trials in patients with recurrent and/or metastatic HNSCC harboring a PI3KCA mutation/amplification and/or a PTEN loss.